Phenoxybenzamine

Phenoxybenzamine

SCHEMBL50729

CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C

The experimentally established mechanism targets of Phenoxybenzamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A known ✓ P08913 1/20 0.97
ADRA2B known ✓ P18089 1/20 0.97
ADRA2C known ✓ P18825 1/20 0.97
ADRA1A known ✓ P35348 1/20 0.97
ALDH1A1 P00352 4/20 1.00
TSHR P16473 4/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
LMNA P02545 2/20 1.00
KDM4E B2RXH2 1/20 1.00
MEN1 O00255 1/20 1.00
GLA P06280 1/20 1.00
CYP3A4 P08684 1/20 1.00
HSPD1 P10809 1/20 1.00
THRB P10828 1/20 1.00
ALOX15 P16050 1/20 1.00
HSPE1 P61604 1/20 1.00
KMT2A Q03164 1/20 1.00
HIF1A Q16665 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
TDP1 Q9NUW8 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenoxybenzamine SCHEMBL202823 0.99 SMN1; SMN2 (1.00) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
Phenoxybenzamine SCHEMBL5722 0.99 SMN1; SMN2 (1.00) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
Phenoxybenzamine SCHEMBL1133740 0.96 SMN1; SMN2 (0.94) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
Phenoxybenzamine SCHEMBL14894820 0.89 SMN1; SMN2 (0.81) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
Phenoxybenzamine SCHEMBL11992656 0.85 ALDH1A1 (0.76) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL15960915 0.85 ALDH1A1 (0.76) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL19958436 0.84 ALDH1A1 (0.74) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL11077715 0.84 SMN1; SMN2 (0.74) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL11682499 0.83 TSHR (0.72) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL11684275 0.82 SMN1; SMN2 (0.71) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2566 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
CN-113687010-B Method for accurately distinguishing echinoid-intermediate ball echinoid from commercial gonad of echinoid 大连海洋大学 2023-09-15 CN claimed
EP-4232004-A1 FRACTAL FORMULATIONS Nanogyre Sprl (BE) 2023-08-30 EP claimed
CN-111743871-B Phenobenzmine hydrochloride tablet and preparation method thereof 天方药业有限公司 2022-04-19 CN claimed
WO-2021078412-A1 FRACTAL FORMULATIONS MESSADEK JALLAL (BE) 2021-04-29 WO claimed
CN-106659789-B CYP2J2 antagonists in the treatment of pain 弗劳恩霍夫应用研究促进协会 2020-11-03 CN claimed
CN-111743871-A Phenobenzmine hydrochloride tablet and preparation method thereof 天方药业有限公司 2020-10-09 CN claimed
US-20200147076-A1 PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME PLATFORM BRIGHTWORKS TWO, LTD. (US) 2020-05-14 US claimed
US-20200121652-A1 COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT THE DOSHISHA (JP) 2020-04-23 US claimed
EP-3639855-A1 COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT The Doshisha (JP) 2020-04-22 EP claimed
WO-1995010275-A1 USE OF ALPHA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC MUSCLE PAIN HUBBARD DAVID R JR (US) 1995-04-20 WO claimed
US-5399581-A Method and compositions for treatment of sexual impotence LARAGH JOHN H (US) 1995-03-21 US claimed
US-5328453-A Method for enhancing transdermal drug delivery of electrical drug applicators DRUG DELIVERY SYSTEMS INC. (US) 1994-07-12 US claimed
CN-1078886-A New medicine \" Zhulinan \" for treating prostatic hyperplasia and uropathy YU CHANGHU (CN) 1993-12-01 CN claimed
US-5261876-A Enhanced peritoneal membrane plasmapheresis MONCRIEF-POPOVICH RESEARCH INSTITUTE, INC. (US) 1993-11-16 US claimed
WO-1992011851-A1 METHOD AND COMPOSITIONS FOR TREATMENT OF SEXUAL IMPOTENCE LARAGH JOHN H (US) 1992-07-23 WO claimed
US-4832684-A PROTEIN REMOVAL; INFUSION OF VASODILATOR THEN DRAINAGE POPOVICH ROBERT P (US) 1989-05-23 US claimed
US-4673385-A INFUSION OF SOLUTION CONTAINING VASODILATOR THEN DRAINAGE FOR TREATMENT OF PLASMA PROTEIN DISEASES POPOVICH ROBERT P 1987-06-16 US claimed
US-4532135-A Treating renal damage by administering vasodilator having postsynaptic alpha-adrenoceptor blocking activity and antihyperlipidemic characteristics EDWARDS K DAVID G 1985-07-30 US claimed
US-4022893-A Treatment for hypertension MOYER JOHN H 1977-05-10 US claimed